Background: Risk for and site of locoregional relapse have not been well studied in patients undergoing gastrectomy with D2 lymphadenectomy for gastric cancer. N1-2) and low-risk (N0) groups were 32⋅4, 12⋅3 and 1⋅7 per cent respectively (P < 0⋅001). Among patients with regional relapse, 90⋅4 per cent had involvement outside the D2 dissected area, and the most commonly involved site was station 16b1. This pattern was maintained in the RPA risk groups (P = 0⋅329).
Introduction
Worldwide, gastric cancer is the third and fifth leading cause of death in men and women respectively 1 . At present, the only curative treatment for gastric cancer is surgery. However, a substantial number of patients experience tumour relapse after gastrectomy 2 . Adjuvant chemoradiotherapy (CRT) and adjuvant or perioperative chemotherapy have been shown to reduce the risk of tumour relapse and to increase survival.
The need for postoperative CRT for gastric cancer in patients undergoing gastrectomy with D2 lymphadenectomy is still debated. The risk of locoregional relapse is low after radical gastrectomy, so the benefit of locoregional radiotherapy may be limited 3, 4 . The survival benefit of postoperative CRT in patients with gastric cancer was established in the USA at a time when gastrectomy with D2 lymphadenectomy was not performed routinely 5 . Furthermore, the Intergroup (INT) 0116 study 5 demonstrated that the survival benefit was probably due to a reduction in locoregional relapse. In the INT-0116 study, the locoregional relapse rate in the surgery-alone arm was 29 per cent, whereas locoregional relapse rates of 5-10 per cent were reported in the surgery-alone arms of the ACTS-GC (Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer) 6 and CLASSIC (capecitabine and oxaliplatin adjuvant study in stomach cancer) 7 trials in which D2 lymphadenectomy was undertaken routinely.
Therapy in Stomach Cancer, ARTIST; ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach, CRITICS) included patients with stage Ib-IV disease. Patients with early-stage gastric cancer are at low risk of locoregional relapse and may not be the best candidates for adjuvant radiotherapy.
In a post hoc analysis of the ARTIST trial 10 , a significant survival benefit was observed in a subgroup of patients who underwent postoperative CRT compared with those who had adjuvant chemotherapy alone. As radiotherapy acts at the tumour bed and is a locoregional treatment, improved survival is likely explained by better locoregional tumour control. Risk factors and predictive models for locoregional control are not well defined and the site of locoregional relapse is still unclear 11 . The aim of this study was to determine which patients are at risk of locoregional relapse after gastrectomy with D2 lymphadenectomy, and to investigate the sites of locoregional relapse.
Methods
Approval was obtained from the institutional review board (IRB 2015-2500-001). Patients who underwent D2 gastrectomy for an adenocarcinoma of the stomach between January 2004 and December 2007 were selected from an institutional database. Patients with distant metastases, those with less than 1 year of follow-up, those who received neoadjuvant chemotherapy, and patients who died within 3 months of operation were excluded.
Surgery
Gastrectomy with D2 lymphadenectomy was carried out by gastric surgeons who had all performed at least 300 gastrectomies for gastric cancer. Subtotal gastrectomy was undertaken if it was possible to resect the tumour at the mid or lower body of the stomach with a sufficient proximal margin.
The dissected nodal regions were classified according to the Japanese Classification of Gastric Carcinoma 12 . Four different compartments were defined: I (nodal stations 1-6), II (stations 7-11), III (stations [12] [13] [14] and IV (stations 15-16). D2 gastrectomy included compartments I and II; in some patients the lymph node dissection included compartment III (27⋅5 per cent) but rarely compartment IV (1⋅3 per cent).
Adjuvant chemotherapy
Adjuvant chemotherapy was recommended for patients with stage II or III tumours. Various regimens were used, most commonly 5-fluorouracil-based ones (Table S1 , supporting information). a physical examination and laboratory tests, with measurement of tumour markers. Abdominopelvic CT was performed every 6 months during the first 3 years and annually for years 4 and 5. Oesophagogastroduodenoscopy was carried out annually. Chest CT, PET, whole-body bone scanning and MRI were performed when relapse was suspected. Pathological confirmation of locoregional relapses was attempted.
Relapses within the potential radiation field were considered a locoregional relapse. Regional relapse was defined as relapse occurring at regional lymph nodes within stations 1-16. Local relapse was defined as any relapse at the site of anastomosis, remnant stomach, duodenal stump or tumour bed. A dedicated radiologist with more than 10 years' experience in gastrointestinal radiology reviewed the radiological findings and confirmed the sites of locoregional relapse.
Statistical analysis
Categorical data were analysed using Fisher's exact test or χ 2 test. The cumulative incidence of locoregional relapse was estimated from date of diagnosis to date of recurrence, taking competing events into consideration, such as non-cancer-related deaths, and the differences were evaluated by means of Gray's test 13 . Recursive partitioning analysis (RPA) was used to stratify the patients according to their risk of locoregional relapse. Variables such as age, sex, T classification, N classification, lymphovascular invasion, perineural invasion, number of dissected nodes, extent of gastrectomy and Laurén classification were included in the RPA. Univariable and multivariable models were generated using Fine and Gray regression analysis 14 . Overall survival after relapse was estimated from the date of relapse to death using the Kaplan-Meier method, and compared with the log rank test. The impact of locoregional relapse on overall survival was evaluated in a multivariable Cox regression model and locoregional relapse was analysed as a time-varying co-variable. All clinicopathological variables were entered into the multivariable model. Two-sided P < 0⋅050 was considered statistically significant. Statistical analyses were carried out in R software version 3.2.2 (R Development Core Team, Vienna, Austria); RPA was performed using 'rpart'. Hazard ratio P Hazard ratio P
Values in parentheses are 95 per cent confidence intervals.
Results
Details of some 3141 patients were retrieved from the database. Excluded were those with distant metastases (204), no primary cancer identified in the stomach (80), histology other than adenocarcinoma (75), less than 1 year of follow-up (72), patients who received neoadjuvant chemotherapy (44), those with missing data (24) , and those who died within 3 months of surgery (24) . Characteristics of the study group (2618 patients) are shown in Table 1 .
Patterns of relapse
With a median follow-up of 78⋅0 (range 28⋅5-122⋅6) months, relapse was diagnosed in 471 of 2618 patients (18⋅0 per cent). Peritoneal metastases were most common (279), followed by locoregional relapse (229) and distant metastasis (167) (Fig. 1a) . Some 86 of 229 patients had locoregional relapse alone, 126 of 229 had synchronous peritoneal and/or distant metastases, and 17 patients had peritoneal and/or distant metastasis preceding locoregional relapse. Locoregional relapse was regional in 178, local in 70, and both regional and local in 19 patients (Fig. 1b) .
Cumulative incidence of locoregional relapse by risk group
The cumulative incidence of locoregional relapse at 5 years was 8⋅5 (95 per cent c.i. 7⋅4 to 9⋅6) per cent. RPA defined (Fig. S1, supporting information) . Patients were initially split between the node-negative and node-positive groups; the latter was then divided into Table 3 Location of regional relapse in 178 patients
Low risk (n = 13) Intermediate risk (n = 62) High risk (n = 103)
Along common hepatic artery 6 (3⋅4) 0 (0) 3 (5) N1-2 and N3 categories. The cumulative incidence of locoregional relapse at 5 years was 1⋅7 (1⋅2 to 2⋅5), 12⋅3 (10⋅0 to 15⋅3) and 32⋅4 (27⋅9 to 37⋅6) per cent in the low-, intermediate-and high-risk groups respectively (P < 0⋅001) (Fig. 2) . Table 2 shows risk factors associated with increased risk of locoregional relapse. Higher T and higher N classification were independent predictors of locoregional relapse. Lymphovascular invasion, perineural invasion and diffuse histological subtype were associated with higher T and N classification ( Table S2 , supporting information).
Multivariable analysis of locoregional relapse

Pattern of locoregional relapse according to risk group
Some 133 patients had involvement of multiple lymph node stations ( Fig. 3 and Table 3 ). Among patients with regional relapse, 9⋅6 per cent had relapse limited to nodal stations 1-11. The most common site of relapse was station 16b1 (107 of 178 patients, 60⋅1 per cent) ( Table 3 ). The pattern of regional relapse was no different between the RPA risk groups (P = 0⋅329). Local relapses were most common at the site of the anastomosis (49 of 70, 70 per cent), followed by the remnant stomach (15 of 70, 21 per cent). The pattern of local relapse was not significantly different among the RPA risk groups (P = 0⋅118).
Survival after relapse and the impact of locoregional relapse
Median overall survival after relapse was 23⋅6 (95 per cent c.i. 20⋅4 to 26⋅8) months. Median overall survival was similar between patients with locoregional relapse alone and those with peritoneal and/or distant metastases only (30⋅1 (19⋅5 to 40⋅7) versus 29⋅8 (25⋅8 to 33⋅8) months; P = 0⋅249), whereas patients with peritoneal and/or distant metastases and locoregional relapse had the poorest median overall survival (13⋅0 (9⋅3 to 16⋅7) months) (P < 0⋅001) (Fig. S2, supporting information) .
Patients who developed a locoregional relapse had an increased risk of death (hazard ratio 3⋅88, 95 per cent c.i. 3⋅19 to 4⋅73), along with older patients and those with perineural invasion, or higher T or N classification. Chemotherapy regimen had no impact on overall survival and LRR (Table S3 , supporting information).
There was no significant difference in median survival after regional relapse for patients who developed recurrence within and those who had recurrence outside the D2 lymph node stations (26⋅4 (13⋅2 to 39⋅6) versus 37⋅2 (29⋅2 to 45⋅2) months respectively; P = 0⋅417).
Discussion
This cohort study defined a risk model for locoregional relapse. The significance of this model is that it can identify patients who may potentially benefit from adjuvant radiotherapy after gastrectomy with D2 lymphadenectomy. The 5-year locoregional relapse rate of 8⋅5 per cent indicates that combining radiotherapy with adjuvant chemotherapy may not be of benefit to all patients. The surgical quality of D2 lymphadenectomy, represented by the high number of dissected lymph nodes, was assured by experienced surgeons from a single high-volume institution that participated in the CLASSIC trial 15 . The sites of locoregional relapse described in the present study are potential fields for targeting adjuvant radiotherapy. N classification was the key factor in stratifying patients according to their risk of locoregional relapse. Because the 5-year locoregional relapse rate exceeded 10 per cent for node-positive patients and was 1⋅7 per cent for node-negative patients, only node-positive patients are potential candidates for postoperative radiotherapy. This is consistent with the results from an unplanned subgroup analysis in the ARTIST trial 10 , which showed that patients with intestinal-type histology or node-positive gastric cancer may benefit from CRT. Updated results from the INT-0116 trial 16 showed that CRT had no survival benefit among patients with the diffuse histological subtype. A study using the Surveillance, Epidemiology, and End Results SEER database (including 1889 patients with diffuse-type histology) 17 , however, did show a survival benefit with adjuvant radiotherapy. In the present study, diffuse subtype was associated with a higher risk of locoregional relapse in univariable but not multivariable analysis, implying an interaction with T and N classification. Currently, Laurén histological type is usually not considered in patient management because of its poor prognostic and predictive strength. Recently, four subgroups have been proposed based on tumour molecular profiling of gastric cancer 18 . At present, secondary analysis of the CLASSIC trial is being conducted, to study the association between molecular subtype and efficacy of chemotherapy with capecitabine and oxaliplatin.
Although all nodal stations can harbour cancer cells, it is thought that lymphatic channels from the stomach first drain into lymph nodes along the greater and lesser curvature, then into nodes around the coeliac axis, and subsequently to the para-aortic nodes. After a D2 lymph node dissection including stations 1-12, optimizing regional control in stations 13-16 is important. Compartment IV and station 16b1 were the most commonly involved sites. This is similar to findings from the ARTIST trial 19, 20 . Lymphatic flow ultimately drains into station 16, the paraaortic region, via four lymphatic pedicles, regardless of the location of the primary tumour 21 .
In a previous study 19 of patients with pN3 nodal disease, locoregional relapse was mainly located outside the D2 dissected field. These sites are associated with poor prognosis, so that tumour deposits here are defined as distant metastases according to the AJCC staging system and the Japanese classification (except for stations 13 and 14v in patients with tumour in the lower or middle part of the stomach, and station 16a2,b1 regardless of tumour location) 12 . In the present study, however, relapse in lymph nodes outside the D2 dissection field was categorized as regional relapse rather than distant metastasis, because these regions may technically be covered easily and safely by the potential radiation field using modern techniques 22 . Furthermore, almost all relapsed lymph nodes outside the D2 dissection field were accompanied by relapsed nodes inside the D2 dissection field, which may not affect the primary outcome. Therefore, nodal regions identified to be at risk in the present study can help determine postoperative radiotherapy fields for patients who have undergone D2 dissection. As relapse outside the D2 nodal stations was similar for the three risk groups, all patients eligible for radiotherapy require comprehensive nodal coverage 23 .
Local relapse was uncommon, with a lower rate than reported previously 20 . The most common location was the anastomotic site followed by the remnant stomach, with no difference between the three risk groups. One of the major variations in radiation fields was the remnant stomach, which was included in the INT-0116 trial but not in the ARTIST trial 24 . The discrepancy between radiotherapy completion rates in the two trials (83 versus 99 per cent respectively) may be explained by the extension of the field of radiation. In the present study, only 15 of 1952 patients who underwent subtotal gastrectomy had a local relapse in the remnant stomach. It therefore seems safe to exclude the remnant stomach from the potential field of radiation.
Although locoregional relapse is less common than peritoneal and/or distant metastases after D2 gastrectomy 7 , it was the second most common type of failure after peritoneal metastasis in the present study, and usually presented as the first event. The association between locoregional relapse and survival has not been well studied. One small study 25 reported a relatively favourable survival in patients with locoregional relapse. In the present study, locoregional relapse was independently associated with poorer overall survival, and patients with isolated locoregional relapse had a similar median survival to patients with isolated peritoneal and/or distant metastases. Considering the incidence, timing and impact on survival, prevention of locoregional relapse is important. Improvement of locoregional control may influence survival when distant metastases can be reduced by improvement of systemic therapy.
This study had several limitations. Although two statistical modelling methods were used for internal validation, external validation is necessary with an independent data set, especially when including Western populations that may have a different tumour biology. Moreover, there was a lack of information on molecular markers such as human epidermal growth factor receptor 2, and chemotherapy regimens were heterogeneous. It is possible that patients with high nodal burdens, such as N3, may not benefit from radiotherapy owing to early peritoneal or systemic failure and death. Furthermore, there may be a subgroup at low risk of locoregional relapse (N1-2 disease) that may be spared adjuvant radiotherapy. The strength of this study is a uniform definition of locoregional relapse based on CT with a relatively consistent follow-up time and all CT images reviewed by an experienced radiologist.
A considerable rate of locoregional relapse (over 10 per cent) was seen in the intermediate-risk (T any N1-2) and high-risk (T any N3) groups. These patients may be candidates for future studies investigating the benefit of adjuvant radiotherapy. The most prevalent sites of relapse were nodes outside the D2 dissected area and this should be acknowledged when designing the radiotherapy field. The ongoing phase III ARTIST II trial 26 , which includes patients with node-positive gastric cancer and randomizes between adjuvant chemotherapy alone and adjuvant CRT, may clarify the benefit adjuvant radiotherapy.
Supporting information
Additional supporting information may be found in the online version of this article: 
